What Does Intermediate Mean in Medical Terms?

“Intermediate” in medical terms describes a result, condition, or risk level that sits between two better-defined categories. It is one of the most common classification words in medicine, yet its practical meaning shifts dramatically depending on the context: an intermediate antibiotic susceptibility result triggers different actions than an intermediate cancer risk score, which in turn differs from an intermediate finding on a lung scan. In every case, though, the label signals that a straightforward yes-or-no answer isn’t available and that further information, testing, or clinical judgment will shape what happens next.

How Antibiotic Susceptibility Testing Uses “Intermediate”

When a lab tests whether a particular antibiotic can kill or inhibit a bacterial infection, the result typically falls into one of three bins: susceptible, intermediate, or resistant. A susceptible result means the drug is expected to work at standard doses. Resistant means it almost certainly will not. Intermediate sits in between: the bacterium might respond if the drug reaches the infection site at higher-than-usual concentrations, but success is not guaranteed at routine dosing.

Standardized testing systems in Europe and the United States define the cutoff points that separate these categories. The European Society for Clinical Microbiology and Infectious Diseases (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) in the U.S. each set breakpoints for specific drug-bug combinations. The development of harmonized standards, such as ISO 20776, has aimed to make the categorization of bacteria as susceptible, intermediate, or resistant more reliable and consistent across laboratories.¹

The intermediate zone is not just a vague gray area — it serves a deliberate technical purpose. When the susceptibility distributions of wild-type (normal) and resistant bacteria overlap, keeping an intermediate zone of a few millimeters in disk-diffusion testing dramatically reduces the chance of major interpretation errors. Without that buffer, labs would more frequently mislabel a resistant organism as susceptible, or vice versa.² In practice, when a clinician sees an intermediate result, the decision often hinges on where the infection is. A urinary tract infection, for example, might still be treatable because certain antibiotics concentrate heavily in urine, effectively reaching the higher levels needed. A bloodstream infection with the same intermediate result would more likely prompt a switch to a different drug.

Cancer Risk Stratification

Oncology uses “intermediate” to describe cancers whose aggressiveness and likely outcomes fall between the least and most dangerous forms of the disease. This is especially prominent in prostate cancer, where classification guidelines divide patients into low-risk, intermediate-risk, and high-risk groups based on factors like tumor grade, PSA levels, and clinical stage.

The intermediate-risk category itself can be subdivided further. National guidelines stratify intermediate-risk prostate cancer into “favorable” and “unfavorable” subgroups, and this distinction matters because the two groups face meaningfully different prognoses and treatment paths. Treatment options for intermediate-risk patients range from active surveillance to surgery and various forms of radiation, but the best approach remains debated, and there is still substantial variability in outcomes even within these subgroups.³ For men with unfavorable intermediate-risk disease, studies have found that brachytherapy (a form of internal radiation) can improve overall survival compared with external beam radiation alone.⁴

Active surveillance, or carefully monitoring a cancer without immediate treatment, is more controversial for intermediate-risk patients than for low-risk ones. Evidence from published surveillance series shows that men with certain higher-grade tumors experience greater rates of clinical progression and are more likely to eventually need treatment than men with lower-grade tumors in the same intermediate-risk bracket.⁵ The word “intermediate” here should not be read as reassuring — it’s a signal that your doctor needs to look more closely at the details within that category.

Intermediate risk also appears in blood cancers. Acute myeloid leukemia (AML), for instance, is classified into favorable, intermediate, and adverse risk groups based on the genetic and chromosomal makeup of the leukemia cells. The European LeukemiaNet guidelines use this three-tier system to guide treatment decisions, including whether a patient should receive a bone marrow transplant.⁶ Within the intermediate-risk AML group, specific mutations can shift the prognosis considerably. The presence of a TET2 mutation, for example, worsens outcomes in patients with intermediate-risk chromosome patterns, especially when combined with other unfavorable genetic markers.⁷

Intermediate Cardiovascular Risk

Heart disease prevention uses scoring tools that estimate your chance of having a heart attack or stroke over the next ten years. These tools assign people to low, intermediate (sometimes called “borderline”), or high risk categories. Someone at intermediate risk has enough concerning factors — age, blood pressure, cholesterol, smoking history — to warrant attention, but not enough to automatically qualify for aggressive treatment like high-dose statins.

This middle zone captures a large portion of the population. In one cohort study, about 13% of participants fell into the intermediate risk category, with men far more likely to land there than women.⁸ The clinical challenge is that many people at intermediate risk will never have a heart attack, while some will. To refine the picture, doctors can add tests like coronary artery calcium (CAC) scoring, a CT scan that measures calcified plaque in heart arteries. Adding CAC results to standard risk scores led to the reclassification of nearly half of all patients studied, with more than half of those originally labeled intermediate risk being moved to a different category — usually lower.⁹

For the person receiving an intermediate risk label, the key takeaway is that this is a starting point, not an endpoint. The label identifies you as someone who deserves closer evaluation, and additional imaging or lab work can often sharpen the picture enough to guide a clearer decision about medications and lifestyle changes.

Intermediate Findings on Diagnostic Scans

Imaging studies sometimes produce results classified as intermediate probability, meaning the scan neither confirms nor rules out the suspected diagnosis. The classic example is the ventilation-perfusion (V/Q) lung scan used to detect pulmonary embolism, a blood clot in the lungs. Scan results are reported as normal, low probability, intermediate probability, or high probability of a clot being present.

An intermediate probability result is frustratingly common. In patients with chronic obstructive pulmonary disease, the V/Q scan usually returns an intermediate reading because the underlying lung disease creates abnormalities that mimic the patterns of a blood clot.¹⁰ When this happens, doctors cannot simply act on the scan result. Further imaging is almost always needed: a retrospective review found that the majority of patients with intermediate probability lung scans underwent additional testing, and more than a third of those who did turned out to have thromboembolic disease.¹¹

CT pulmonary angiography (CTPA) has become the go-to follow-up when a V/Q scan returns an intermediate result. It can often clarify whether a clot is present, though even a negative CTPA cannot definitively exclude a pulmonary embolism in every case.¹² In practice, the V/Q scan’s intermediate category has been one of the reasons CTPA has largely replaced it as the first-choice imaging test in many hospitals — CTPA gives a more definitive answer and leaves fewer patients in diagnostic limbo.

Tumor Grading and Pathology

When a pathologist examines tissue under a microscope, tumors are often assigned a grade that reflects how abnormal the cells look and how quickly they appear to be dividing. Many grading systems use a three-tier scheme — low, intermediate, and high grade — and the intermediate category carries distinct clinical meaning.

Neuroendocrine tumors illustrate this well. Low-grade neuroendocrine tumors tend to be slow-growing, while high-grade tumors are extremely aggressive. Intermediate-grade tumors occupy a less predictable middle ground: they typically behave with moderate aggressiveness, but their clinical course is harder to forecast than either extreme.¹³ For patients, an intermediate-grade tumor means the treatment plan may be more individualized, since the tumor’s behavior cannot be as confidently predicted.

Genetics and the Intermediate Allele

In genetics, “intermediate” often describes a measurement that hovers near the boundary between normal and disease-causing. Huntington disease provides a clear example. The condition is caused by a stretch of CAG repeats in a specific gene. Alleles with 36 or more repeats cause the disease; those below 27 are considered normal. Alleles with 27 to 35 repeats are classified as “intermediate.” People carrying intermediate alleles generally do not develop Huntington disease themselves.¹⁴

The concern with intermediate alleles is what they may do in the next generation. These repeat sequences are unstable during reproduction and can expand when passed to a child, potentially crossing the threshold into the disease-causing range. The risk is not equal across the intermediate spectrum. Alleles with 34 repeats have about a 2.4% chance of expanding into the disease range, while those with 35 repeats carry a roughly 21% risk of producing a new Huntington mutation.¹⁵ This kind of information is important for genetic counseling: someone with an intermediate allele needs to understand that they are unlikely to develop the disease but that their children could be at risk, depending on the exact repeat count.

A different genetic use of “intermediate” appears in blood disorders. Beta-thalassemia intermedia describes a form of the inherited blood condition that falls in severity between thalassemia minor (the mild carrier state) and thalassemia major (the severe form requiring regular transfusions). Patients with thalassemia intermedia have a wide range of outcomes — some manage well with minimal treatment, while others develop complications like skeletal changes, an enlarged spleen, and heart problems if left untreated.¹⁶

Intermediate Care in Hospitals

Outside of test results and diagnoses, “intermediate” also describes a level of hospital care. Stepdown units, also called intermediate care units, are wards designed for patients who are too sick for a regular hospital floor but not sick enough to need the intensive care unit. These beds provide closer monitoring and more nursing attention than a general ward, without the full apparatus of an ICU — ventilators, one-to-one nursing ratios, and continuous invasive monitoring.¹⁷ If a family member is moved from the ICU to an intermediate care unit, it usually means they are improving. If they are admitted to one from the emergency department, it means their condition warrants more attention than a standard room can provide.

Intermediate-Acting Medications

Pharmacology uses “intermediate” to describe how long a drug’s effects last. The best-known example is NPH insulin, often labeled an “intermediate-acting” insulin. NPH takes about three hours to start working, peaks at roughly six to seven hours, and lasts around thirteen hours.¹⁸ That profile sits between rapid-acting insulins (which peak quickly and fade within a few hours) and long-acting insulins (which provide a steady background level over a full day). NPH’s intermediate profile means it produces a noticeable peak in blood-sugar-lowering effect, unlike the flatter curve of newer long-acting formulations.¹⁹ For people with diabetes, this means that the timing of meals and injections matters more with NPH than with newer basal insulins.

Intermediate-Density Lipoproteins

Most people are familiar with LDL (“bad” cholesterol) and HDL (“good” cholesterol), but there is a lipoprotein particle that falls between them in density. Intermediate-density lipoproteins (IDL) are a transitional form: as the liver processes larger fat-carrying particles, it breaks them down into IDL, which are then further converted into LDL. IDL particles do not normally linger in the bloodstream for long, but when they accumulate, they appear to contribute to artery disease.

Research has found that even moderately elevated IDL cholesterol levels are closely associated with a high frequency of coronary artery disease, and that IDL cholesterol was a significant independent predictor of disease in men.²⁰ A separate study tracking disease progression over five years found that changes in IDL levels strongly predicted worsening of coronary artery disease, even after accounting for LDL levels.²¹ Standard lipid panels do not routinely measure IDL, which is one reason this particle gets less public attention than LDL despite its apparent role in heart disease.

Why the Intermediate Category Frustrates Patients

Receiving an “intermediate” result of any kind can be psychologically difficult. Research on patients with uncertain diagnoses shows that the ambiguity itself affects psychological well-being, decision-making, and behavior in ways that go beyond simple worry. The experience of not fitting neatly into a clear category generates a form of distress that is distinct from the distress of a confirmed bad diagnosis.²²

The reality is that “intermediate” rarely means “we have no idea what is going on.” It almost always means “we know more than nothing but less than enough,” and the next step is usually well-defined — a follow-up test, a repeat scan in a few months, a specialist referral, or a change in the monitoring plan. The label reflects a genuine biological ambiguity, not a failure of the medical system, and it exists because forcing an intermediate finding into either the “normal” or “abnormal” bin would lead to worse decisions for patients.

How the Intermediate Label Shapes Treatment Decisions

Across all these contexts, the intermediate category shares a common clinical function: it identifies the zone where protocol-driven medicine reaches its limits and individualized judgment takes over. Low-risk patients can often be reassured and monitored lightly. High-risk patients usually have clear treatment pathways. Intermediate patients require the clinician to weigh additional factors — patient preferences, comorbidities, family history, and sometimes additional testing — before settling on a plan.

In some specialties, the intermediate category has been deliberately narrowed over time as better tests become available. The shift from V/Q scanning to CTPA in diagnosing pulmonary embolism, for instance, has reduced the number of patients left with an intermediate probability result. Similarly, genetic sub-typing in leukemia has allowed doctors to reclassify many patients out of the broad intermediate-risk bin and into more actionable categories. The trend in medicine is to shrink the intermediate zone wherever possible, not because the concept is flawed but because the ideal is always a clearer answer. Until then, understanding what “intermediate” means in your specific situation — and what the planned next step is — gives you a more useful frame than treating the word as a synonym for “unknown.”